[1] Riccabona G, Decristoforo C.  Peptide targeted imaging of cancer[J]. Cancer Biother Radiopharm, 2003, 18(5): 675-687.   doi: 10.1089/108497803770418238
[2] Said SI, Mutt V.  Polypeptide with broad biological activity: isolation from small intestine[J]. Science, 1970, 169(951): 1217-1218.
[3] Onoue S, Matsumoto A, Nagano Y, et al.  Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences[J]. Eur J Pharmacol, 2004, 485(1-3): 307-316.   doi: 10.1016/j.ejphar.2003.11.046
[4] Hoare SR.  Mechanisms of peptide and non-peptide ligand binding to Class B G-protein-coupled receptors[J]. Drug Discov Today, 2005, 10(6): 417-427.   doi: 10.1016/S1359-6446(05)03370-2
[5] Laburthe M, Couvineau A, Marie JC.  VPAC receptors for VIP and PACAP[J]. Receptors Channels, 2002, 8(3-4): 137-153.   doi: 10.3109/10606820213680
[6] Laburthe M, Couvineau A.  Molecular pharmacology and structure of VPAC Receptor for VIP and PACAP[J]. Regul Pept, 2002, 108(2-3): 165-173.   doi: 10.1016/S0167-0115(02)00099-X
[7] Bokaei PB, Ma XZ, Byczynski B, et al.  Identification and characterization of five-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors[J]. Genomics, 2006, 88(6): 791-800.   doi: 10.1016/j.ygeno.2006.07.008
[8] Reubi JC.  In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging[J]. J Nucl Med, 1995, 36(10): 1846-1853.
[9] Reubi JC, Läderach U, Waser B, et al.  Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin[J]. Cancer Res, 2000, 60(11): 3105-3112.
[10] Moody TW, Jensen RT.  Breast cancer VPAC1 receptors[J]. Ann N Y Acad Sci, 2006, 1070: 436-439.   doi: 10.1196/annals.1317.058
[11] Virgolini I, Yang Q, Li S, et al.  Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors[J]. Cancer Res, 1994, 54(3): 690-700.
[12] Koch TR, Michener SR, Go VL.  Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea[J]. Gastroenterology, 1991, 100(1): 99-106.   doi: 10.1016/0016-5085(91)90588-C
[13] Hejna M, Hamilton G, Brodowicz T, et al.  Serum levels of vasoactive intestinal peptide(VIP)in patients with adenocarcinomas of the gastrointestinal tract[J]. Anticancer Res, 2001, 21(2A): 1183-1187.
[14] Collado B, Carmena MJ, Clemente C, et al.  Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model[J]. Peptides, 2007, 28(9): 1896-1901.   doi: 10.1016/j.peptides.2007.04.015
[15] Valdehita A, Carmena MJ, Collado B, et al.  Vasoactive intestinal peptide(VIP)increases vascular endothelial growth factor(VEGF)expression and secretion in human breast cancer cells[J]. Regul Pept, 2007, 144(1-3): 101-108.   doi: 10.1016/j.regpep.2007.06.006
[16] ValdehitaA, BajoAM, Fernández-Martínez AB, etal.  Nuclear localization of vasoactive intestinal peptide(VIP)receptors in human breast cancer[J]. Peptides, 2010, 31(11): 2035-2045.   doi: 10.1016/j.peptides.2010.07.024
[17] Virgolini I, Raderer M, Kurtaran A, et al.  Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors[J]. N Engl J Med, 1994, 331(17): 1116-1121.   doi: 10.1056/NEJM199410273311703
[18] Raderer M, Kurtaran A, Hejna M, et al.  123I-labelled vasoactive intestinal peptide receptorscintigraphy in patients with colorectal cancer[J]. Br J Cancer, 1998, 78(1): 1-5.   doi: 10.1038/bjc.1998.433
[19] RadererM, KurtaranA, Yang Q, et al.  Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer[J]. J Nucl Med, 1998, 39(9): 1570-1575.
[20] Pallela VR, Thakur ML, Chakder S, et al.  99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies[J]. J Nucl Med, 1999, 40(2): 352-360.
[21] Rao PS, Thakur ML, Pallela V, et al.  99mTc labeled VIP analog: evaluation for imaging colorectal cancer[J]. Nucl Med Biol, 2001, 28(4): 445-450.   doi: 10.1016/S0969-8051(01)00205-0
[22] Virgolini I, Traub T, Ofluoglu S, et al.  Human biodistribution, safety and absorbed dose of 99mTc-P1666 vasoactive intestinal peptide(VIP)receptor scintigraphy[J]. J Nucl Med, 1999, 40: 244(abstract)-.
[23] Thakur ML, Marcus CS, Saeed S, et al.  Imaging tumors in humans with Tc-99m-VIP[J]. Ann N Y Acad Sci, 2000, 921: 37-44.
[24] Kothari K, Prasad S, Korde A, et al.  99mTc(CO)3-VIP analogues: preparation and evaluation as tumor imaging agent[J]. Appl Radiat Isot, 2007, 65(4): 382-386.   doi: 10.1016/j.apradiso.2006.11.001
[25] Moody TW, Leyton J, Unsworth E, et al.  (Arg15, Arg21)VIP: evaluation of biological activity and localization to breast cancer tumors[J]. Peptides, 1998, 19(3): 585-592.   doi: 10.1016/S0196-9781(97)00459-2
[26] Cheng DF, Yin DZ, Zhang L, et al.  Preparation of the novel fluorine-18-labeled VIP analog for PET imaging studies using two different synthesis methods[J]. J Fluorine Chem, 2007, 128(3): 196-201.   doi: 10.1016/j.jfluchem.2006.12.007
[27] Zhang K, Aruva MR, Shanthly N, et al.  Vasoactive intestinal peptide(VIP)and pituitary adenylate cyclase activating peptide(PACAP)receptorspecific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation[J]. Regul Pept, 2007, 144(1-3): 91-100.   doi: 10.1016/j.regpep.2007.06.008
[28] Zhang K, Aruva MR, Shanthly N, et al.  PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer[J]. J Nucl Med, 2008, 49(1): 112-121.   doi: 10.2967/jnumed.107.043703
[29] Moody TW, Zia F, Draoui M, et al.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth[J]. Proc Natl Acad Sci U S A, 1993, 90(10): 4345-4349.   doi: 10.1073/pnas.90.10.4345
[30] Moody TW, Jensen RT, Fridkin M, et al.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist[J]. J Mol Neurosci, 2002, 18(1-2): 29-35.   doi: 10.1385/JMN:18:1-2:29
[31] Moody TW, Czerwinski G, Tarasova NI, et al.  VIP-ellipticine derivatives inhibit the growth of breast cancer cells[J]. Life Sci, 2002, 71(9): 1005-1014.   doi: 10.1016/S0024-3205(02)01741-1
[32] Moody TW, Czerwinski G, Tarasova NI, et al.  The development of VIP-ellipticine conjugates[J]. Regul Pept, 2004, 123(1-3): 187-192.   doi: 10.1016/j.regpep.2004.03.021
[33] Moody TW, Mantey SA, Fuselier JA, et al.  Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells[J]. Peptides, 2007, 28(9): 1883-1890.   doi: 10.1016/j.peptides.2007.04.017